CN103003308B - 抗icam-1抗体在治疗患有复发性癌症的患者中的用途 - Google Patents

抗icam-1抗体在治疗患有复发性癌症的患者中的用途 Download PDF

Info

Publication number
CN103003308B
CN103003308B CN201180034613.1A CN201180034613A CN103003308B CN 103003308 B CN103003308 B CN 103003308B CN 201180034613 A CN201180034613 A CN 201180034613A CN 103003308 B CN103003308 B CN 103003308B
Authority
CN
China
Prior art keywords
antibody
icam
cells
cancer
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180034613.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103003308A (zh
Inventor
玛尔库斯·翰松
比约恩·弗伦多斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioinvent International AB
Original Assignee
Bioinvent International AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent International AB filed Critical Bioinvent International AB
Publication of CN103003308A publication Critical patent/CN103003308A/zh
Application granted granted Critical
Publication of CN103003308B publication Critical patent/CN103003308B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180034613.1A 2010-07-13 2011-07-13 抗icam-1抗体在治疗患有复发性癌症的患者中的用途 Expired - Fee Related CN103003308B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1011771.1 2010-07-13
GBGB1011771.1A GB201011771D0 (en) 2010-07-13 2010-07-13 Biological material and particular uses thereof
PCT/EP2011/061983 WO2012007516A1 (en) 2010-07-13 2011-07-13 Use of antibodies against icam-1 in the treatment of patients with relapsed cancer

Publications (2)

Publication Number Publication Date
CN103003308A CN103003308A (zh) 2013-03-27
CN103003308B true CN103003308B (zh) 2016-08-10

Family

ID=42712312

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180034613.1A Expired - Fee Related CN103003308B (zh) 2010-07-13 2011-07-13 抗icam-1抗体在治疗患有复发性癌症的患者中的用途

Country Status (10)

Country Link
US (2) US20130189260A1 (enExample)
EP (1) EP2593481A1 (enExample)
JP (2) JP5992406B2 (enExample)
KR (1) KR20130100977A (enExample)
CN (1) CN103003308B (enExample)
AU (1) AU2011278350B2 (enExample)
CA (1) CA2805200A1 (enExample)
GB (1) GB201011771D0 (enExample)
RU (1) RU2593709C2 (enExample)
WO (1) WO2012007516A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
GB2495113A (en) * 2011-09-29 2013-04-03 Bioinvent Int Ab Anti-ICAM-1 antibody for treating multiple-myeloma-related disorders
HK1215174A1 (zh) 2012-11-29 2016-08-19 Bayer Healthcare Llc 針對活化蛋白c的人源化單克隆抗體及其用途
CN104812402A (zh) * 2012-11-29 2015-07-29 拜尔健康护理有限责任公司 针对活化蛋白C (aPC)的单克隆抗体
GB201300346D0 (en) * 2013-01-09 2013-02-20 Biolnvent Internat Ab BiologIcal materials and uses thereof
WO2015148971A2 (en) 2014-03-27 2015-10-01 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
KR101674874B1 (ko) 2014-10-21 2016-11-22 한국원자력의학원 항암제 내성 예측용 바이오마커로서의 ｉｃａｍ－３ 및 이의 용도
US9795624B2 (en) 2015-05-04 2017-10-24 Research Foundation Of The City University Of New York Cationic polymers as co-drugs for chemotherapeutic agents
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
AU2017207370B2 (en) * 2016-01-12 2021-09-23 University Of Southern California Use of long-term fasting mimicking as dietary treatment for multiple myeloma and other cancers
AU2017261723B2 (en) 2016-05-11 2023-02-09 University Of Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases.
US11284640B2 (en) 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
CA3056797A1 (en) 2017-03-16 2018-09-20 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
CN109949256B (zh) * 2019-01-14 2023-04-07 昆明理工大学 一种基于傅里叶变换的天文图像融合方法
KR20210124310A (ko) 2019-02-06 2021-10-14 벤테라, 인코포레이티드 국소 포스포이노시티드 3-키나제 억제제
JP2023535280A (ja) * 2020-07-20 2023-08-17 エフエヌシーティー バイオテック、インコーポレイテッド 大腸癌転移阻害剤をスクリーニングする方法
JP2023538265A (ja) * 2020-08-04 2023-09-07 ベンセラ，インコーポレイティド ホスホイノシチド３－キナーゼ阻害剤の製剤
KR20230107115A (ko) 2022-01-07 2023-07-14 서울대학교병원 항-icam-1 항체의 단기요법을 이용한 간이식 거부반응의 억제방법
UY40783A (es) 2023-06-12 2024-12-31 Amgen Inc Proteínas de unión a agonistas del receptor beta de linfotoxina

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101360760A (zh) * 2005-12-12 2009-02-04 生物发明国际公司 生物材料及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ZA883159B (en) * 1987-05-04 1990-01-31 Dana Farber Cancer Inst Inc Intercellular adhesion molecules and their binding ligands
US5643872A (en) 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US6008058A (en) 1993-06-18 1999-12-28 University Of Louisville Cyclic peptide mixtures via side chain or backbone attachment and solid phase synthesis
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
CN102099684A (zh) * 2008-02-29 2011-06-15 国立大学法人信州大学 前哨淋巴结内转移癌细胞检测试剂盒
GB0903151D0 (en) * 2009-02-25 2009-04-08 Bioinvent Int Ab Antibody uses and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101360760A (zh) * 2005-12-12 2009-02-04 生物发明国际公司 生物材料及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma;LACY MARTHA Q 等;《JOURNAL OF CLINICAL ONCOLOGY 》;20080701;第26卷(第19期);3196-3203 *

Also Published As

Publication number Publication date
JP2013539454A (ja) 2013-10-24
KR20130100977A (ko) 2013-09-12
RU2013105769A (ru) 2014-08-20
EP2593481A1 (en) 2013-05-22
CA2805200A1 (en) 2012-01-19
US20160280788A1 (en) 2016-09-29
RU2593709C2 (ru) 2016-08-10
GB201011771D0 (en) 2010-08-25
AU2011278350A1 (en) 2013-01-10
JP5992406B2 (ja) 2016-09-14
CN103003308A (zh) 2013-03-27
JP2016175906A (ja) 2016-10-06
US20130189260A1 (en) 2013-07-25
WO2012007516A1 (en) 2012-01-19
AU2011278350B2 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
CN103003308B (zh) 抗icam-1抗体在治疗患有复发性癌症的患者中的用途
JP7575102B2 (ja) Ｍｕｃ１８に特異的な抗体
US20210220472A1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
US20190209682A1 (en) Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
US9803013B2 (en) Biological materials and uses thereof
JP7656330B2 (ja) Ｃｄ４４に特異的な抗体
EP3621694B1 (en) Lrrc33 inhibitors and use thereof
KR20190008171A (ko) 항-bcma 폴리펩티드 및 단백질
CN101939336A (zh) Axl抗体
CN107614010A (zh) 结合至flt3蛋白的抗体药物偶联物(adc)
KR20090088878A (ko) 신규한 항증식 항체
KR20200118458A (ko) 개선된 면역치료 효과를 갖지만 약화된 부작용을 갖는 돌연변이 항-ctla-4 항체
US20120087916A1 (en) Anti-icam-1 antibody, uses and methods
US20180221482A1 (en) Use of antibodies against icam-1 in combination with an anti cancer drug in the treatment of patients
CN114630679A (zh) 抗garp抗体和免疫调节剂的组合
CA2997130C (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
HK40103766A (en) Lrrc33 inhibitors and use thereof
EA045239B1 (ru) СПЕЦИФИЧНЫЕ К ИЗОФОРМЕ, ПЕРМИССИВНЫЕ ПО ОТНОШЕНИЮ К КОНТЕКСТУ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160810

Termination date: 20180713